{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:47:14Z","timestamp":1789958834737,"version":"4.0.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,10,6]],"date-time":"2015-10-06T00:00:00Z","timestamp":1444089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1038\/leu.2015.270","type":"journal-article","created":{"date-parts":[[2015,10,6]],"date-time":"2015-10-06T06:41:00Z","timestamp":1444113660000},"page":"57-64","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":93,"title":["Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study"],"prefix":"10.1038","volume":"30","author":[{"given":"A","family":"Hochhaus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Rosti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N C P","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J L","family":"Steegmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"le Coutre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Ossenkoppele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Petrov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Masszi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Hellmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Griskevicius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Wiktor-Jedrzejczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Rea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Coriu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T H","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Porkka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Saglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Gastl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M C","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Schuld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Di Matteo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Pellegrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2047-2526","authenticated-orcid":false,"given":"L","family":"Dezzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F-X","family":"Mahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Baccarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F J","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,6]]},"reference":[{"key":"BFleu2015270_CR1","unstructured":"Tasigna [package insert]. Novartis Pharmaceuticals Corporation: East Hanover, NJ, USA, 2015."},{"key":"BFleu2015270_CR2","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1182\/blood-2013-06-510396","volume":"123","author":"TP Hughes","year":"2014","unstructured":"Hughes TP, Saglio G, Kantarjian HM, Guilhot F, Niederwieser D, Rosti G et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood 2014; 123: 1353\u20131360.","journal-title":"Blood"},{"key":"BFleu2015270_CR3","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1038\/leu.2012.134","volume":"26","author":"RA Larson","year":"2012","unstructured":"Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012; 26: 2197\u20132203.","journal-title":"Leukemia"},{"key":"BFleu2015270_CR4","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","volume":"12","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011; 12: 841\u2013851.","journal-title":"Lancet Oncol"},{"key":"BFleu2015270_CR5","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251\u20132259.","journal-title":"N Engl J Med"},{"key":"BFleu2015270_CR6","unstructured":"Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre PD, Lobo C et al. Efficacy and safety of nilotinib vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase: 6-year follow-up of ENESTnd. Haematologica 2015; 100 (61), (abstract P228)."},{"key":"BFleu2015270_CR7","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3324\/haematol.2013.091272","volume":"99","author":"TP Hughes","year":"2014","unstructured":"Hughes TP, le Coutre PD, Jootar S, Reiffers J, Turkina AG, Saglio G et al. ENESTnd 5-year follow-up: continued benefit of frontline nilotinib (NIL) compared with imatinib (IM) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP). Haematologica 2014; 99: 236\u2013237 (abstract S677).","journal-title":"Haematologica"},{"key":"BFleu2015270_CR8","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029\u20131035.","journal-title":"Lancet Oncol"},{"key":"BFleu2015270_CR9","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013; 122: 515\u2013522.","journal-title":"Blood"},{"key":"BFleu2015270_CR10","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","volume":"32","author":"P Rousselot","year":"2014","unstructured":"Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 2014; 32: 424\u2013430.","journal-title":"J Clin Oncol"},{"key":"BFleu2015270_CR11","doi-asserted-by":"crossref","unstructured":"Rea D, Nicolini FE, Tulliez M, Rousselot P, Guilhot F, Gardembas M et al. Dasatinib or nilotinib discontinuation in chronic phase (CP)-chronic myeloid leukemia (CML) patients (pts) with durably undetectable BCR-ABL transcripts: interim analysis of the STOP 2G-TKI study with a minimum follow-up of 12 months\u2014on behalf of the French CML Group Filmc. Blood 2014; 124: (abstract 811).","DOI":"10.1182\/blood.V124.21.811.811"},{"issue":"15_suppl","key":"BFleu2015270_CR12","doi-asserted-by":"publisher","first-page":"TPS7124","DOI":"10.1200\/jco.2014.32.15_suppl.tps7124","volume":"32","author":"Francois-Xaxier Mahon","year":"2014","unstructured":"Mahon FX, Baccarani M, Mauro MJ, Hughes TP, Saglio G, Savona M et al. Treatment-free remission (TFR) following nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom, ENESTop, ENESTgoal, and ENESTpath. J Clin Oncol 2014; 32: (abstract TPS7124).","journal-title":"Journal of Clinical Oncology"},{"key":"BFleu2015270_CR13","doi-asserted-by":"crossref","unstructured":"Mahon FX, Richter J, Guilhot J, Muller MC, Dietz C, Porkka K et al. Interim analysis of a pan European Stop Tyrosine Kinase Inhibitor trial in chronic myeloid leukemia: the EURO-SKI study. Blood 2014; 124: (abstract 151).","DOI":"10.1182\/blood.V124.21.151.151"},{"key":"BFleu2015270_CR14","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","volume":"118","author":"J Hasford","year":"2011","unstructured":"Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 2011; 118: 686\u2013692.","journal-title":"Blood"},{"key":"BFleu2015270_CR15","first-page":"186","volume":"8","author":"NC Cross","year":"1994","unstructured":"Cross NC, Melo JV, Feng L, Goldman JM . An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia 1994; 8: 186\u2013189.","journal-title":"Leukemia"},{"key":"BFleu2015270_CR16","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1038\/leu.2012.104","volume":"26","author":"NCP Cross","year":"2012","unstructured":"Cross NCP, White H, M\u00fcller MC, Saglio G, Hochhaus A . Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 2012; 26: 2172\u20132175.","journal-title":"Leukemia"},{"key":"BFleu2015270_CR17","unstructured":"National Cancer Institute NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. National Cancer Institute: Bethesda, MD, USA, 2009."},{"key":"BFleu2015270_CR18","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","volume":"32","author":"R Hehlmann","year":"2014","unstructured":"Hehlmann R, M\u00fcller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-Study IV. J Clin Oncol 2014; 32: 415\u2013423.","journal-title":"J Clin Oncol"},{"key":"BFleu2015270_CR19","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3324\/haematol.2013.095158","volume":"99","author":"G Etienne","year":"2014","unstructured":"Etienne G, Dulucq S, Nicolini FE, Morrisset S, Fort MP, Schmitt A et al. Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy. Haematologica 2014; 99: 458\u2013464.","journal-title":"Haematologica"},{"key":"BFleu2015270_CR20","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1002\/ajh.23560","volume":"88","author":"L Falchi","year":"2013","unstructured":"Falchi L, Kantarjian HM, Wang X, Verma D, Quint\u00e1s-Cardama A, O'Brien S et al. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol 2013; 88: 1024\u20131029.","journal-title":"Am J Hematol"},{"key":"BFleu2015270_CR21","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1038\/leu.2015.152","volume":"29","author":"F Castagnetti","year":"2015","unstructured":"Castagnetti F, Gugliotta G, Breccia M, Stagno F, Iurlo A, Albano F et al. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. Leukemia 2015; 29: 1823\u20131831.","journal-title":"Leukemia"},{"key":"BFleu2015270_CR22","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/leu.2015.36","volume":"29","author":"L Kalmanti","year":"2015","unstructured":"Kalmanti L, Saussele S, Lauseker M, M\u00fcller MC, Dietz CT, Heinrich L et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia 2015; 29: 1123\u20131132.","journal-title":"Leukemia"},{"key":"BFleu2015270_CR23","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/leu.2015.29","volume":"29","author":"NCP Cross","year":"2015","unstructured":"Cross NCP, White HE, Colomer D, Ehrencrona H, Foroni L, Gottardi E et al. Laboratory recommendations for scoring deep molecular response following treatment for chronic myeloid leukemia. Leukemia 2015; 29: 999\u20131003.","journal-title":"Leukemia"},{"key":"BFleu2015270_CR24","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/leu.2015.73","volume":"29","author":"VS Hoffmann","year":"2015","unstructured":"Hoffmann VS, Baccarani M, Hasford J, Lindoerfer D, Burgstaller S, Sertic D et al. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European countries. Leukemia 2015; 29: 1336\u20131343.","journal-title":"Leukemia"},{"key":"BFleu2015270_CR25","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1038\/leu.2012.85","volume":"26","author":"B Hanfstein","year":"2012","unstructured":"Hanfstein B, M\u00fcller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 2012; 26: 2096\u20132102.","journal-title":"Leukemia"},{"key":"BFleu2015270_CR26","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","volume":"123","author":"E Jabbour","year":"2014","unstructured":"Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boqu\u00e9 C et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 2014; 123: 494\u2013500.","journal-title":"Blood"},{"key":"BFleu2015270_CR27","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","volume":"30","author":"D Marin","year":"2012","unstructured":"Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2012; 30: 232\u2013238.","journal-title":"J Clin Oncol"},{"key":"BFleu2015270_CR28","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122: 872\u2013884.","journal-title":"Blood"},{"key":"BFleu2015270_CR29","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia, v1., National Comprehensive Cancer Network: Fort Washington, PA, USA 2015."},{"key":"BFleu2015270_CR30","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1038\/leu.2014.153","volume":"28","author":"B Hanfstein","year":"2014","unstructured":"Hanfstein B, Shlyakhto V, Lauseker M, Hehlmann R, Saussele S, Dietz C et al. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia 2014; 28: 1988\u20131992.","journal-title":"Leukemia"},{"key":"BFleu2015270_CR31","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1182\/blood-2014-03-566323","volume":"124","author":"S Branford","year":"2014","unstructured":"Branford S, Yeung DT, Parker WT, Roberts ND, Purins L, Braley JA et al. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood 2014; 124: 511\u2013518.","journal-title":"Blood"},{"key":"BFleu2015270_CR32","unstructured":"Steegmann JL, Casado Montero LF, G\u00f3mez-Casares MT, Rozman M, Echeveste MA, Garcia-Gutierrez V et al. Very early molecular responses in the first two months of therapy are highly predictive of deep molecular responses at 18 months, in chronic myeloid leukemia patients treated upfront with nilotinib. Haematologica 2014; 99 (75) (abstract P281)."},{"key":"BFleu2015270_CR33","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/cam4.433","volume":"4","author":"RW Marsh","year":"2015","unstructured":"Marsh RW, Talamonti MS, Katz MH, Herman JM . Pancreatic cancer and FOLFIRINOX: a new era and new questions. Cancer Med 2015; 4: 853\u2013863.","journal-title":"Cancer Med"},{"key":"BFleu2015270_CR34","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1177\/1758834014566428","volume":"7","author":"SJ Welsh","year":"2015","unstructured":"Welsh SJ . Corrie PG. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther Adv Med Oncol 2015; 7: 122\u2013136.","journal-title":"Ther Adv Med Oncol"},{"key":"BFleu2015270_CR35","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1177\/1758834014548187","volume":"6","author":"AJ Dooley","year":"2014","unstructured":"Dooley AJ, Gupta A, Bhattacharyya M, Middleton MR . Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case series. Ther Adv Med Oncol 2014; 6: 262\u2013266.","journal-title":"Ther Adv Med Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/leu2015270.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2015270","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2015270.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T18:05:15Z","timestamp":1684433115000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2015270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,6]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["BFleu2015270"],"URL":"https:\/\/doi.org\/10.1038\/leu.2015.270","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,6]]},"assertion":[{"value":"9 July 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Authors declare the following relationships with pharmaceutical companies: Novartis\u2014receipt of honoraria (AHo, GR, NC, JS, PlC, TM, LG, WWJ, DR, DC, TB, GS, MM, FXM, MB, FG), research funding (all authors), nonfinancial support (GR, WWJ, DC, TB), employment (PS, PDM, AP, LD) and stock ownership (PS); Pfizer\u2014receipt of honoraria (AHo, GR, JS, PlC, DR, DC, TB, GS, FXM, MB), research funding (AHo, GR, JS, TB) and nonfinancial support (GR, TB); Ariad\u2014receipt of honoraria (AHo, GR, NC, JS, PlC, DR, TB, GS, MM, FXM, MB), research funding (AHo, GR, JS, MM) and nonfinancial support (GR, TB); Bristol-Myers Squibb\u2014receipt of honoraria (AHo, GR, JS, PlC, TM, DR, DC, TB, GS, MM, FXM, MB), research funding (AHo, GR, JS, MM) and nonfinancial support (GR, TB).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}